Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of VCD versus RCD in first-relapse multiple myeloma
2010-021557-40Phase 3Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bortezomib, lenalidomide, cyclophosphamide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: CR and VGPR rate. Started Mar 2012; status: completed.
02
Drugs
bortezomiblenalidomidecyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2010-021557-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021557-40.